ITI-214

a phosphodiesterase 1 inhibitor with nootropic activity

Also Known As:

2-(4-(6-fluoropyridin-2-yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-hexahydrocyclopenta(4,5)imidazo(1,2-a)pyrazolo(4,3-e)pyrimidin-4-(2H)-one

Networked: 5 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - ITI-214: 5

Experts

1.	Davis, Robert E: 2 articles (01/2021 - 01/2020)
2.	Snyder, Gretchen L: 2 articles (01/2021 - 01/2020)
3.	Chen, Shih-Ann: 1 article (09/2021)
4.	Chen, Yao-Chang: 1 article (09/2021)
5.	Chen, Yi-Jen: 1 article (09/2021)
6.	Huang, Jen Hung: 1 article (09/2021)
7.	Lin, Yung-Kuo: 1 article (09/2021)
8.	Liu, Chih Min: 1 article (09/2021)
9.	Yugo, Dony: 1 article (09/2021)
10.	Agunbiade, Tolu A: 1 article (01/2021)

Related Diseases

1.	Heart Failure 01/01/2021 - "Single-dose ITI-214 is well-tolerated and confers inodilator effects in humans with heart failure with reduced ejection fraction. " 01/01/2021 - "Patients with heart failure with reduced ejection fraction were randomized 3:1 to 10, 30, or 90 mg ITI-214 single oral dose or placebo (n=9/group). " 01/01/2021 - "Here, we assessed pharmacokinetics, hemodynamics, and tolerability of single-dose ITI-214 in humans with stable heart failure with reduced ejection fraction. " 01/05/2024 - "Among them, ITI-214 has entered Phase II clinical trials, holding promise for the treatment of Parkinson's disease and heart failure. "
2.	Parkinson Disease (Parkinson's Disease) 01/05/2024 - "Among them, ITI-214 has entered Phase II clinical trials, holding promise for the treatment of Parkinson's disease and heart failure. "
3.	Hypertrophy 01/01/2021 - "An 8-week treatment with 100 mg/kg per day ITI-214 improved endothelium-independent relaxation in both aorta and coronary arteries, at least partly restored the diminished reactive hyperemia, lowered the systolic and diastolic blood pressure, normalized the carotid hypertrophy, and ameliorated inflammatory responses exclusively in Ercc1Δ/- mice. "
4.	Hyperemia 01/01/2021 - "An 8-week treatment with 100 mg/kg per day ITI-214 improved endothelium-independent relaxation in both aorta and coronary arteries, at least partly restored the diminished reactive hyperemia, lowered the systolic and diastolic blood pressure, normalized the carotid hypertrophy, and ameliorated inflammatory responses exclusively in Ercc1Δ/- mice. "
5.	Atrial Fibrillation 09/01/2021 - "This study explored the effects of PDE-1 inhibition using ITI-214 on electrical activity in the pulmonary vein (PV), the most common trigger of atrial fibrillation, and investigated the underlying ionic mechanisms. "